Cargando…

Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study

BACKGROUND: The rise of drug-resistant tuberculosis (DR-TB) has presented a substantial challenge to the national tuberculosis (TB) control program. Understanding the epidemiology of pre-extensively drug-resistant tuberculosis (pre-XDR-TB) could help clinicians to adapt MDR-TB treatment regimens at...

Descripción completa

Detalles Bibliográficos
Autores principales: Diriba, Getu, Alemu, Ayinalem, Tola, Habteyes Hailu, Yenew, Bazezew, Amare, Misikir, Eshetu, Kirubel, Sinshaw, Waganeh, Abebaw, Yeshiwork, Meaza, Abyot, Seid, Getachew, Moga, Shewki, Zerihun, Betselot, Getu, Melak, Dagne, Biniyam, Mollalign, Hilina, Tadesse, Mengistu, Buta, Bedo, Wordofa, Niguse, Alemu, Ephrem, Erresso, Ashenafi, Hailu, Michael, Tefera, Zigba, Wondimu, Amanuel, Belhu, Tegegn, Gamtesa, Dinka Fekadu, Getahun, Muluwork, Kebede, Abebaw, Abdela, Saro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513164/
https://www.ncbi.nlm.nih.gov/pubmed/36176268
http://dx.doi.org/10.1016/j.ijregi.2022.08.012
_version_ 1784797996267864064
author Diriba, Getu
Alemu, Ayinalem
Tola, Habteyes Hailu
Yenew, Bazezew
Amare, Misikir
Eshetu, Kirubel
Sinshaw, Waganeh
Abebaw, Yeshiwork
Meaza, Abyot
Seid, Getachew
Moga, Shewki
Zerihun, Betselot
Getu, Melak
Dagne, Biniyam
Mollalign, Hilina
Tadesse, Mengistu
Buta, Bedo
Wordofa, Niguse
Alemu, Ephrem
Erresso, Ashenafi
Hailu, Michael
Tefera, Zigba
Wondimu, Amanuel
Belhu, Tegegn
Gamtesa, Dinka Fekadu
Getahun, Muluwork
Kebede, Abebaw
Abdela, Saro
author_facet Diriba, Getu
Alemu, Ayinalem
Tola, Habteyes Hailu
Yenew, Bazezew
Amare, Misikir
Eshetu, Kirubel
Sinshaw, Waganeh
Abebaw, Yeshiwork
Meaza, Abyot
Seid, Getachew
Moga, Shewki
Zerihun, Betselot
Getu, Melak
Dagne, Biniyam
Mollalign, Hilina
Tadesse, Mengistu
Buta, Bedo
Wordofa, Niguse
Alemu, Ephrem
Erresso, Ashenafi
Hailu, Michael
Tefera, Zigba
Wondimu, Amanuel
Belhu, Tegegn
Gamtesa, Dinka Fekadu
Getahun, Muluwork
Kebede, Abebaw
Abdela, Saro
author_sort Diriba, Getu
collection PubMed
description BACKGROUND: The rise of drug-resistant tuberculosis (DR-TB) has presented a substantial challenge to the national tuberculosis (TB) control program. Understanding the epidemiology of pre-extensively drug-resistant tuberculosis (pre-XDR-TB) could help clinicians to adapt MDR-TB treatment regimens at an earlier stage. This study aimed to assess second-line anti-TB drug resistance among MDR-TB patients in Ethiopia using routine laboratory-based data. METHODS: Laboratory-based cross-sectional data were collected from the national TB reference laboratory and seven regional tuberculosis culture laboratories in Ethiopia from July 2019 to March 2022. The required data, such as drug-susceptibility testing (DST) results and sociodemographics, were collected on a structured checklist from laboratory registration books and electronic databases. Data were entered into a Microsoft Excel spreadsheet and analyzed using SPSS version 23. Descriptive statistics were performed to show the distribution and magnitude of drug resistance. RESULTS: Second-line drugs (SLDs) susceptibility testing was performed for 644 MDR isolates, of which 19 (3%) were found to be pre-XDR-TB cases. Of the total MDR-TB isolates, 19 (3%) were resistant to at least one fluoroquinolone drug, while 11 (1.7%) were resistant to at least one injectable second-line drug. Of the 644 MDR-TB isolates, 1.9% (5/261) pre-XDR were from new MDR-TB cases, while 3.7% (14/383) were from previously treated MDR-TB patients. The most frequently identified mutations, based on MTBDRsl results, were in codon A90V of the gyrA gene (77.3%) and A1401G of the rrs gene (45.5%). CONCLUSION: The overall prevalence of pre-XDR-TB in Ethiopia is considerable. The majority of SLD resistance mutations were in the gyrA gene at position A90V. Modern, rapid DST is necessary to enable identification of pre-XDR-TB and XDR-TB in supporting proper regimen administration for patients.
format Online
Article
Text
id pubmed-9513164
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95131642022-09-28 Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study Diriba, Getu Alemu, Ayinalem Tola, Habteyes Hailu Yenew, Bazezew Amare, Misikir Eshetu, Kirubel Sinshaw, Waganeh Abebaw, Yeshiwork Meaza, Abyot Seid, Getachew Moga, Shewki Zerihun, Betselot Getu, Melak Dagne, Biniyam Mollalign, Hilina Tadesse, Mengistu Buta, Bedo Wordofa, Niguse Alemu, Ephrem Erresso, Ashenafi Hailu, Michael Tefera, Zigba Wondimu, Amanuel Belhu, Tegegn Gamtesa, Dinka Fekadu Getahun, Muluwork Kebede, Abebaw Abdela, Saro IJID Reg Title Page BACKGROUND: The rise of drug-resistant tuberculosis (DR-TB) has presented a substantial challenge to the national tuberculosis (TB) control program. Understanding the epidemiology of pre-extensively drug-resistant tuberculosis (pre-XDR-TB) could help clinicians to adapt MDR-TB treatment regimens at an earlier stage. This study aimed to assess second-line anti-TB drug resistance among MDR-TB patients in Ethiopia using routine laboratory-based data. METHODS: Laboratory-based cross-sectional data were collected from the national TB reference laboratory and seven regional tuberculosis culture laboratories in Ethiopia from July 2019 to March 2022. The required data, such as drug-susceptibility testing (DST) results and sociodemographics, were collected on a structured checklist from laboratory registration books and electronic databases. Data were entered into a Microsoft Excel spreadsheet and analyzed using SPSS version 23. Descriptive statistics were performed to show the distribution and magnitude of drug resistance. RESULTS: Second-line drugs (SLDs) susceptibility testing was performed for 644 MDR isolates, of which 19 (3%) were found to be pre-XDR-TB cases. Of the total MDR-TB isolates, 19 (3%) were resistant to at least one fluoroquinolone drug, while 11 (1.7%) were resistant to at least one injectable second-line drug. Of the 644 MDR-TB isolates, 1.9% (5/261) pre-XDR were from new MDR-TB cases, while 3.7% (14/383) were from previously treated MDR-TB patients. The most frequently identified mutations, based on MTBDRsl results, were in codon A90V of the gyrA gene (77.3%) and A1401G of the rrs gene (45.5%). CONCLUSION: The overall prevalence of pre-XDR-TB in Ethiopia is considerable. The majority of SLD resistance mutations were in the gyrA gene at position A90V. Modern, rapid DST is necessary to enable identification of pre-XDR-TB and XDR-TB in supporting proper regimen administration for patients. Elsevier 2022-08-30 /pmc/articles/PMC9513164/ /pubmed/36176268 http://dx.doi.org/10.1016/j.ijregi.2022.08.012 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Title Page
Diriba, Getu
Alemu, Ayinalem
Tola, Habteyes Hailu
Yenew, Bazezew
Amare, Misikir
Eshetu, Kirubel
Sinshaw, Waganeh
Abebaw, Yeshiwork
Meaza, Abyot
Seid, Getachew
Moga, Shewki
Zerihun, Betselot
Getu, Melak
Dagne, Biniyam
Mollalign, Hilina
Tadesse, Mengistu
Buta, Bedo
Wordofa, Niguse
Alemu, Ephrem
Erresso, Ashenafi
Hailu, Michael
Tefera, Zigba
Wondimu, Amanuel
Belhu, Tegegn
Gamtesa, Dinka Fekadu
Getahun, Muluwork
Kebede, Abebaw
Abdela, Saro
Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study
title Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study
title_full Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study
title_fullStr Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study
title_full_unstemmed Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study
title_short Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study
title_sort pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in ethiopia: a laboratory-based surveillance study
topic Title Page
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513164/
https://www.ncbi.nlm.nih.gov/pubmed/36176268
http://dx.doi.org/10.1016/j.ijregi.2022.08.012
work_keys_str_mv AT diribagetu preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT alemuayinalem preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT tolahabteyeshailu preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT yenewbazezew preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT amaremisikir preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT eshetukirubel preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT sinshawwaganeh preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT abebawyeshiwork preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT meazaabyot preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT seidgetachew preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT mogashewki preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT zerihunbetselot preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT getumelak preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT dagnebiniyam preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT mollalignhilina preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT tadessemengistu preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT butabedo preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT wordofaniguse preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT alemuephrem preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT erressoashenafi preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT hailumichael preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT teferazigba preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT wondimuamanuel preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT belhutegegn preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT gamtesadinkafekadu preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT getahunmuluwork preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT kebedeabebaw preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy
AT abdelasaro preextensivelydrugresistanttuberculosisamongmultidrugresistanttuberculosispatientsinethiopiaalaboratorybasedsurveillancestudy